Prothena | PRTA - Ebitda


Prothena reported $-39.53M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Immunic USD -22.78M 753K Jun/2024
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Prothena USD -39.53M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024